****

**Supplementary Figure 1:** Improvement of the ESS, PDSS, and PDQ-39 scores after treatment with selegiline in PD patients with EDS. EDS: Excessive daytime sleepiness; ESS: Epworth Sleepiness Scale; PD: Parkinson’s disease; PDQ-39: Parkinson’s Disease Quality of Life Questionnaire 39; PDSS: Parkinson’s Disease Sleep Scale.

**Supplementary Table 1: Parkinson’s disease patients with motor fluctuation and dyskinesia at baseline and after 8 weeks of treatment,** ***n* (%).**

|  |  |  |  |
| --- | --- | --- | --- |
| **Item** | **Baseline** | **Week 8** | ***P*-value** |
| Motor fluctuation |  |  | 0.022 |
|  Yes | 50 (41.3) | 42 (34.7) |  |
|  No | 71 (58.7) | 79 (65.3) |  |
| Motor fluctuation improvement |  |  | 0.037 |
|  0 | 71 (58.7) | 79 (65.3) |  |
|  1%–25% | 34 (28.1) | 30 (24.8) |  |
|  26%–50% | 13 (10.7) | 9 (7.4) |  |
|  51%–75% | 1 (0.8) | 1 (0.8) |  |
|  76%–100% | 2 (1.7) | 2 (1.7) |  |
| Dyskinesia |  |  | 1.000 |
|  Yes  | 8 (6.6) | 8 (6.6) |  |
|  No  | 113 (93.4) | 113 (93.4) |  |
| Dyskinesia improvement |  |  | 1.000 |
|  0 | 113 (93.4) | 113 (93.4) |  |
|  1%–25% | 8 (6.6) | 8 (6.6) |  |
|  26%–50% | 0 | 0 |  |
|  51%–75% | 0 | 0 |  |
|  76%–100% | 0 | 0 |  |